Bicara Therapeutics (NASDAQ:BCAX) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report issued on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $48.00 price target on the stock.

Several other brokerages also recently issued reports on BCAX. Cantor Fitzgerald initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating on the stock. Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target on the stock. Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective for the company. Finally, TD Cowen assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $43.33.

Bicara Therapeutics Trading Down 0.7 %

Shares of Bicara Therapeutics stock opened at $23.60 on Tuesday. Bicara Therapeutics has a 1 year low of $18.33 and a 1 year high of $28.09.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was purchased at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the transaction, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Ra Capital Management, L.P. bought 1,833,000 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at $77,461,524. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder James E. Flynn purchased 70,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the purchase, the insider now directly owns 897,587 shares of the company’s stock, valued at $16,156,566. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Investors Weigh In On Bicara Therapeutics

A hedge fund recently bought a new stake in Bicara Therapeutics stock. First Turn Management LLC bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 562,391 shares of the company’s stock, valued at approximately $14,324,000. Bicara Therapeutics makes up 2.3% of First Turn Management LLC’s portfolio, making the stock its 24th biggest position. First Turn Management LLC owned about 1.09% of Bicara Therapeutics as of its most recent filing with the SEC.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.